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ABSTRACT 
Objective: It is to develop a simple, valid and rapid chromatographic method for quantification of saxagliptin in rat’s serum in order to study 
saxagliptin pharmacokinetics parameters in sucralose fed rats simultaneously to detect any interaction possibility between saxagliptin and 
sucralose in rats.  
Methods: In our developed method of analysis, mobile phase was consisted of phosphate buffer (pH =4) and methanol (70:30) v/v at flow rate of 1 
ml/min with UV detection at 230 nm., C8 column of separation was used with the temperature of 40 °C using injection volume of 50 µl, samples run 
time was 10 min, and sildenafil citrate was used as internal standard. Saxagliptin was given to rats orally of (2g/kg) dose while sucralose was given 
with (11 mg/kg/day) dose.  
Results: A successful HPLC method was validated and developed to determine saxagliptin in rats serum, overall intra-day precision and accuracy 
were reasonable with coefficient of variation percentage CV % values range (o.14-4.03) and accuracy % range (99.5-104), while inter-day precision 
and accuracy showed accepted precision with CV% range (0.15-2.81) and accuracy % range (99.9-116). The coefficient of correlation was 0.99949 
with reasonable sensitivity and selectivity. Combination effect of saxagliptin with sucralose on saxagliptin serum profile was demonstrated as 
strong statistical effect according to Cohen’s d and significant P values too.  
Conclusion: A successful HPLC method was validated and developed to quantify saxagliptin in rats serum, combination effect of saxagliptin with 
sucralose over all time intervals of saxagliptin serum profile was demonstrated as strong statistical effect.  
Keywords: HPLC, Saxagliptin, Sucralose, Pharmacokinetic, Interaction. 
 
INTRODUCTION 
Saxagliptin: ((±)-5-(4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) 
methyl)-2, 4-) thiazolidinedione monohydrochloride [1], the 
structural formula is as shown in fig. 1. It belongs to a different 
chemical class with different pharmacological action than the 
sulfonylureas, metformin, or the α-glucosidase inhibitors [2], it is a 
compound that belongs to a group named “thiazolidinediones” 
family, an oral antidiabetic agent that acts by decreasing insulin 
resistance [3]. Saxagliptin has the same mechanism of action by 
which all thiazolidinediones act inside the body. Its mechanism of 
action made it as one of the most effective drugs that is used in the 
management of type 2 diabetes mellitus [4, 5], saxagliptin can 
improve the sensitivity to insulin in muscle and adipose tissue [2, 
7] which helps in hepatic gluconeogenesis inhibition [8] and 
improves glycemic control by reducing circulating insulin levels [9, 
10].  
Type 2 diabetes patients are usually treated with numerous 
pharmacological compounds which increases the susceptibility to be 
exposed to risky drug-drug interactions [7].  
Saxagliptin was marketed at USA in 1999, now a days; it is marketed 










Fig. 1: Saxagliptin hydrochloride chemical structure 
Saxagliptin is extensively metabolized by hydroxylation and 
oxidation via liver CYP450 enzymatic system [8], in vitro data 
emphasized that multiple CYP isoforms are involved in saxagliptin 
metabolism, mostly: CYP2C8 and CYP3A4 [10, 17]. 
Sucralose is a synthetic organochlorine sweetener, with chemical 
formula of Dichloro- 1, 6-dideoxy-β-D-fructofuranosyl-4-chloro-4-
deoxy α-D-galactopyranoside [11], the chemical structure is shown in 
fig. 2. It is considered as one of the most common sweeteners in the 
world’s food industries [12] and pharmaceutical manufacturing 
[13]. 
Sucralose is a derivative of the halogenated sucrose, mellow, with 
aromatic flavor and good stability, low in calories (around 3 calories 
per 1 gm), there are significant gaps in our current knowledge 
concerning pharmacokinetics of these sweeteners and their 
potential for sweetener–drug interactions. Recently, previous 
studies have approved that sucralose increases the expression of the 
P-glycoprotein intestinal transporter and induces CYP3A4 enzyme 
activity in intestine and liver [14, 15] at levels that have been 
associated with reduced bioavailability, pharmacokinetic and 
pharmacodynamic parameters of drug, it may occur if the drug is to 
be metabolized by CYP3A4 enzyme and concurrently taken with 
sucralose at doses that are approved by the FDA, these findings 




Fig. 2: Sucralose chemical structure 
In our current study we aimed to design a new, simple, valid and rapid 











International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                  Vol 7, Issue 9, 2015 
Innovare 
Academic Sciences 
Abu Dayyih et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 243-250 
244 
according to EMEA guidelines for quantification of saxagliptin in rat 
serum in presence and absence of sucralose to determine any possible 
interaction between both substances through the monitoring of 
saxagliptin serum levels when sucralose is given concurrently. 
MATERIALS AND METHODS 
Chemicals 
High performance liquid chromatography-ultraviolet HPLC/UV is a 
technique of analysis that could be used for determination of several 
compounds in plasma or serum [16, 18]. 
Methanol and phosphate buffer HPLC gradient were used for HPLC 
analysis (FULLTIME, USA), deionized water HPLC gradient was 
obtained from (TEDIA, USA), while saxagliptin hydrochloride raw 
material was from (JPM, Jordan). 
Sildenafil citrate, the internal standard was purchased from 
(YASHICA pharmaceuticals, India), while sucralose was acquired 
from its finished product Splenda®.  
Apparatus and chromatographic conditions 
The HPLC system (HITACHI, Japan) consisted of S # L-2130 VWR-
HITACHI pump model, S# L-2200 VWR-HITACHI auto sampler 
thermostat, S# L-2300 VWR-HITACHI column oven and S# L-2420 
VWR-HITACHI UV detector. 
Chromatographic separation was carried out using mobile phase 
consisted of (70:30) v/v phosphate buffer and methanol with pH of 
4, column of separation was (ACE C8, 5 µm (250 x 4.6 mm i.d.) at 
temperature of 40 °C using injection volume of 50 µl, mobile phase 
flow rate was 1 ml/min and samples run time was 10 min, the 
signals were monitored and analyzed at λ= 230 nm and sildenafil 
citrate was used as internal standard. 
Preparation of stock and working solutions 
Saxagliptin oral dose of (2g/kg/day) was recommended for rats and 
prepared by dissolving the drug in methanol while sucralose oral 
dose of (11 mg/kg/day) was prepared as a working solution of (250 
mg/ml) Splenda®, sucralose solution was prepared by dissolving 
Splenda®powder with distilled water at room temperature under 
sonication, both working solutions were prepared freshly and 
directly before experiment and kept away of heat and light. 
Saxagliptin stock solution was prepared by dissolving (25 mg) in 
50 ml methanol to get a stock solution of 500 µg/ml while 
saxagliptin working solutions were prepared from the stock 
solution by dilution with methanol directly before use and kept 
away of light and heat sources, sildenafil citrate was used as 
internal standard. 
Calibration samples  
Serial dilutions of samples were prepared by taking an appropriate 
volume of each working concentration that is previously prepared in 
methanol with sufficient volume of rats serum was added to reach 5 
ml final volume with corresponding calibration concentration. 
Samples were vortexed, then used for analysis procedure, all final 
standard solutions were prepared freshly and directly before 
analysis. Six different calibration concentrations were analyzed 
under the same HPLC conditions for each calibration curve, peak 
area ratios were calculated and the correlation coefficient r² was 
accepted if it is more than 0.98. 
Sample preparation (Extraction procedure)  
Sample preparation was done by mixing 100 µl of serum with 75.0 µl 
of internal standard IS working solution, then sample was vortexed 
for 30 seconds and centrifuged at 12000 rpm for 5 min. Supernatant 
was transferred into rack, and 50 µl of supernatant was injected into 
HPLC unit. 
Precision and accuracy  
To examine and evaluate the precision and accuracy of our method 
of analysis, four different concentrations were prepared and used; 
lower limit of quantification, low, middle and high concentrations of 
saxagliptin by spiking with rats serum. 
Intra-day precision and accuracy were evaluated by analyzing the 
four concentrations five times sequently in the same day while the 
same procedure was done at three different days for inter-day 
precision and accuracy evaluation. 
Precision was assessed by comparing each concentration with the 
CV% (coefficient of variation) while the accuracy was assessed by 
comparing the mean calculated concentration with±20% of spiked 
concentration for lower limit of quantification while it was 
compared with±15% for other quality control samples. 
Stability  
Room temperature stability: three samples of quantification control 
low concentration (QCL  ) and quantification control high 
concentration)QCH) of concentrations (2 and 12.8 µg/ml) were 
prepared and analyzed with freshly prepared calibration at zero 
time and after 8 hs at room temperature of 28 °C. Area ratios % per 
QCL and QCH were calculated referring to related calibration. 
Freeze and thaw stability: Three samples of QCL and QCH were 
prepared properly in serum with sufficient final volume covering all 
test cycles analysis.  
At zero time: with corresponding calibration, samples were analyzed 
and concentrations were calculated, then, samples were stored and 
frozen at-20 °C. 
After 12 hs: samples were thawed at room temperature 25 °C which 
was the samples processing temperature during analysis stages. 
After complete thawing, samples were analyzed again with 
corresponding calibration, and refrozen again for 24 h. 
After 24 hs: Samples were thawed and analyzed under the same 
conditions. After each cycle, concentrations were calculated 
referring to related calibration.  
Long term stability: three samples of (QCL and QCH) were analyzed 
with freshly prepared calibration at zero time. Samples then were 
frozen for 30 days at temperature of-20 °C. After long term freezing 
period was finished, samples were removed and thawed at room 
temperature.  
Room temperature and long term stability test were also carried out 
for working solutions, stability test was assessed by comparing the 
calculated concentrations with the nominated concentrations as it 
should be within±15% for both QCL and QCH. 
Preclinical study  
The study protocol was approved by the Research Committee 
(October; 5/10/2013) at the Faculty of Pharmacy, University of 
Petra, Amman, Jordan. 
Adult male Sprague Dawley laboratory rats were supplied at Petra 
University Animal House. Rat average weights were (0.230 kg±0.03). 
Rats were placed in air-conditioned environment with temperature 
of (20-25 °C) and exposed to a photoperiod cycle (12 h light/12 h 
dark) with humidity of 50% daily. Rats were under fasting for 24 hs, 
and weighed directly before the experiment. All used rats were in 
healthy conditions before and after experiment as rats were 
monitored for one month post analysis.  
Saxagliptin and sucralose test solutions were freshly prepared 
directly in the laboratory before rats feeding in order to avoid any 
possible decomposition of either saxagliptin or sucralose.  
A group consisting of total 80 healthy rats was used for the 
experiment. Rats were divided into groups of 8 rats, rats then were 
weighed and numbered orderly. Saxagliptin and sucralose oral doses 
were calculated according to each rat weight then given orally 
according to ordered numbers using gastric gavage. Trials analysis 
was performed among 3 days according to following arrangement:  
At first day of trials: four groups of rats were used for analysis; 
two groups have received water at experiment zero time, then 
followed by saxagliptin after 1 h of water feeding, while the other 
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two group have received sucralose at zero time of experiment 
followed by saxagliptin after 1h (of sucralose feeding. Time 
intervals of blood samples pooling were: 0, 30 minutes, 1 h, 2 h, 3 
h, 4 h, 6 h, 8 h and 24 h. 
At second day of trials: two groups have received water at zero time 
of experiment followed by saxagliptin after one h, while other two 
groups have received sucralose at zero time followed by saxagliptin 
after 1 h of sucralose feeding. Time intervals of blood samples 
pooling were: 0, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h.  
At third day of trials: two groups have received water at zero 
time of experiment followed by saxagliptin after one h, while the 
other two groups have received sucralose at zero time followed 
by saxagliptin after 1 h of sucralose feeding. Time intervals of 
blood samples pooling were: 0, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h 
and 24 h. 
Tail tip of each rat was cut after weighing and numbering, 
approximately 200 µl of blood was pooled into eppendorf tube at 
each time interval under the same numbering order, after total time 
intervals of blood pooling is finished, samples were centrifuged for 
10 minutes (12000 rpm) in order to obtain pure serum that is 
needed for analysis than frozen at-20 °C. 
RESULTS AND DISCUSSION 
Acceptable separation of saxagliptin and sildenafil citrate in serum 
was obtained as the saxagliptin peaks were sharp with no tailing or 
splitting, reasonable retention time and clear chromatograms, as 
mentioned in fig. 3, 4, 5 and 6 which represents an overlay 
chromatograms for blank rats serum, rats serum with IS, rats serum 
with LLOQ, and rats serum with IS and saxagliptin after 30 minutes 
of combination respectively. 
Precision, accuracy and linearity were measured to estimate the 
method performance. 
Linearity calibration curves were designed with six different trials, 
method calibration curves and correlation coefficient were collected 
after 6 replications, the correlation coefficient and calibrations 
equations were mentioned in table 1. 
 
Table 1: Linearity calibration curves data for six calibration curves 
Calibration no. Calibration equation Correlation coefficient (r²)value 
Calibration 1 y = 0.100898 x-0.00098911 0.999888 
Calibration 2 y = 0.109219 x+0.00043395 0.999776 
Calibration 3 y=0.099599 x-0.001155059 0.999166 
Calibration 4 y = 0.101335 x-0.005413046 0.999990 
Calibration 5 y = 0.098772 x+0.00257727 0.998991 
Calibration 6 y = 0.096640 x-0.01064449 0.999111 
 
High correlation coefficient which was over 0.99 for all calibrations 
indicated the reasonability of method linearity between the peak 
area ratio of saxagliptin in the serum and the quality control 
concentrations used in calibrations. 
Inter-day and intra-day precision showed acceptable values as LLOQ 
the lower limit of quantification showed coefficient of variation 
(CV%) less than 20% while QCL, quantification control medium 
concentration QCM and QCH represented coefficient of variation 
values less than 15%, inter-day and intra-day results mentioned in 
table 2. 
On the other hand, Inter-day and intra-day accuracy showed 
reasonable values as mean calculated concentration of LLOQ was 
within±20 % of nominated concentration while it was within±15 % 
for QCL, QCM and QCH. 
 
Table 2: Inter-day over three days and intra-day precision and accuracy for QC samples 
Inter-day: Day 1 
Sample ID Mean SD CV% Error Accuracy % 
ST(LLOQ) 0.26 0.0046 1.78 0.01 104 
QCL 1.999 0.0038 0.191 0.01 99.95 
QCM 7.10 0.0915 1.29 0.10 101.42 
QCH 13.51 0.1229 0.91 0.15 105.54 
Inter-day: Day 2 
ST(LLOQ) 0.25 0.0041 1.44 0.01 100 
QCL 2.01 0.0030 0.15 0.02 100 
QCM 7.31 0.0979 1.34 0.31 104 
QCH 13.52 0.4502 3.33 0.60 105 
Inter-day: Day 3 
ST(LLOQ) 0.25 0.0038 1.55 -0.004 100 
QCL 2.14 0.0089 0.42 0.043 107 
QCM 7.32 0.0856 1.17 0.42 104.57 
QCH 13.71 0.3852 2.81 1.01 107.11 
Intra-day 
ST(LLOQ) 0.26 0.0035 1.35 0.01 104 
QCL 1.99 0.0027 0.14 -0.01 99.5 
QCM 7.16 0.0959 1.34 0.16 102.2 
QCH 13.31 0.5363 4.03 0.51 103.9 
Three different stability tests were designed and carried out to assess the drug samples stability under all possible conditions that could be kept 
under among all experimental phases. 
 
Freeze and thaw stability: data were obtained after each cycle of analysis for two quality control (QC) concentrations; QCL and QCH, 
samples were analyzed at zero time then after 12 h of freezing, samples were thawed for 3 hs then analyzed and finally after another 24 h of 
freezing and thawing, stability percentages were over 99% and accuracy percentages were over 98%. See fig. 9. All results were listed in 
table 3. 
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Table 3: Freeze and thaw stability data for QCL and QCH 
QC Low (2 µg/ml) 
Time Mean Accuracy% Stability % 
0 h 2.01 103  
102 
99.8 
12 h 1.98 99.99 99 
99.98 
99.97 
24 h 1.99 99.98 99.5 
99.98 
99.87 
QC High (12.8 µg/ml) 
Time Mean Accuracy% Stability % 
0 h 12.7 99.68  
99.89 
99.79 
12 h 12.75 98.90 99.9 
98.79 
98.99 





Fig. 3: Freeze and thaw stability chromatogram 
 
Room temperature stability: serum samples of both QCL and QCH were analyzed at zero times and after 8 h of standing at room temperature of (28 
°C±1), both stability and accuracy percentages were over 99%, see fig. 10, data was mentioned in table 4. 
 
 
Fig. 4: Room temperature stability chromatograms 
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Table 4: Room temperature stability data for saxagliptin in serum for QCL and QCH 
QC Low (2 µg/ml) 
Time (h) Mean Accuracy% Stability% 
0 h 2.1 110 99.8 
106 
100 
8 h 2.08 105 
99 
99 
QC High (12.8 µg/ml) 
Time (h) Mean Accuracy% Stability% 
0 h 12.79 99.9 99.9 
100.1 
99.9 




Table 5: Long term stability data of saxagliptin in serum for QCL and QCH 
QC Low (2 µg/ml) 
Time Mean Accuracy% Stability% 
0 h 1.98 99.72 99.90 
99.25 
99.74 
30 days 1.99 100.90 
99.91 
99.50 
QC High (12.8 µg/ml) 
Time Mean Accuracy% Stability% 
0 h  98.89 99.88 
98.51 
99.35 




Table 6: First day trial serum data (number of groups) N=2 for both drug alone and drug with sweetener 
Day-1-trials 
SX alone, N=2 
SX+sucralose, N=2 
Serum average concentrations (µg/ml) 





10.992 15.139 13.003 10.939 8.941 6.203 0.511 
Group 3+4 
(SX+sucralose) 
5.006 10.016 12.082 11.087 10.031 7.014 4.649 0.202 
 
Long term freezing stability test was carried out as serum samples of 
both QCL and QCH were analyzed at zero time and after freezing for 
30 days and thawing for 3 h, stability percentages were over 99% 
while accuracy % were over 98%,see fig. 11, data was collected then 
listed in table 5. 
Sucralose–saxagliptin combination effect on saxagliptin serum levels: 
Rats serum levels of saxagliptin were calculated through serum 
samples analysis that obtained from rats groups per day of trials. 
At first day of trials the samples were collected starting by zero time 
and ending by 24 h as last time interval,(fig. 3), samples were 
analyzed and data collected properly as in table 6. 
At the second day of trials the samples were collected starting by 
zero time and ending by 24 h as last time interval, (fig. 4), samples 
were analyzed and data collected properly as in table 7. 
At the third day of trials the samples were collected starting by zero 
time and ending by 8 hs as last time interval, (fig. 5), samples were 
analyzed and data collected properly as in table 8. 
 
Fig. 5: Long term stability chromatograms 
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Fig. 6: First day trial serum–time profile curve 
 
 
Fig. 7: Second day trial serum–time profile curve 
 
Table 7: Second day trial data (number of groups) N=2 for both drug alone and drug with sweetener 
Day-2-trials 
SX alone, N=2 
SX+sucralose, N=2 
Serum average concentrations (µg/ml) 
Group no. 30 min 1 h 2 h 3 h 4 h 6 h 8 h 24 h 
Group 1+2 
(SX alone) 
5.981 10.686 15.298 13.143 12.491 9.627 6.898 0.579 
Group 3+4  
(SX+sucralose) 
5.146 10.274 12.130 11.241 10.125 8.035 5.145 0.313 
 
Table 8: Third day trial data (number of groups) N=2 for both drug alone and drug with sweetener 
Day-3-trials 
SX alone, N=2 
SX+sucralose, N=2 
Serum average concentrations (µg/ml) 
Group no. 30 min 1 h 2 h 3 h 4 h 6 h 8 h 24 h 








10.801 6.690 0.595 










8.707 5.011 0.302 
 
 
Three days of trials results were collected with overall calculated 
serum concentrations profiles corresponding area under the curve 
(AUC) values, maximum concentration (Cmax) and maximum time 
(Tmax) were summarized in table 9, with statistical results, (fig. 6). 
 
Fig. 8: Third day trial serum–time profile curve 
 
Fig. 9: Serum concentration–time profile graph (0-24) h of oral 
administration of drug, (SX = saxagliptin alone, SX Plus = 
saxagliptin with sucralose)
 
Table 9: Serum concentration–time profile kinetic parameters 
Drug C max (µg/ml) T max (h) T ½ (h) AUC (µg/mlh) 
SX 15.237±0.03 2 2 130.6±2.1 
SX plus sucralose 12.078±0.1 2 2 100±2.0 
P value  0.009** **P ˂ 0.01 0.001** 
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Concentrations values were treated statistically to evaluate the 
effect size and significance of combination between saxagliptin and 
sucralose,   Cohen’s d value was used for effect size evaluation of 
combination while P value was used for estimation of combination 
significance, Combination effect size values were exceeding 0.8 for 
all intervals except at 30 minutes as it was smaller, combination 
effect significance was strong as all P values were less than 0.01, 
Two examples of analysis chromatograms during HPLC procedure 
run were mentioned below (figure7 and fig. 8). 
 
 
Fig. 10: Blank chromatogram (1) and separation chromatogram 
(2): Saxagliptin (b peak) and internal standrad slidenafil citrate 
(a peak) chromatogram 
 
 
Fig. 11: Saxagliptin chromatogram 
 
Method validation was evaluated referring to EMEA guidelines 
Precision and accuracy results were reasonable as CV% values and 
mean calculated concentrations were within range of acceptance 
while method linearity performance was accepted as all correlation 
coefficients were over 0.98. 
For method stability: three stability tests showed reasonable results, 
which confirm method stability as accuracy percentages and 
stability percentages were accepted with reasonable values. 
Method of analysis was designed with a novel mobile phase 
consistence and low cost comparing with previously used mobile 
phases in other methods. 
Sucralose–saxagliptin combination effect was first demonstrated in 
current research.  
The statistical analysis of the results showed a significant 
combination interaction between saxagliptin and sucralose when 
both compounds are given concurrently, as P values represented 
strong combination effects, which were less than 0.01. 
This combination interaction could be justified by sucralose 
induction effect on CYP 450 enzymes, specifically 3A4 subtype by 
which saxagliptin is extensively metabolized by it. 
Saxagliptin is basically absorbed in stomach where CYP3A4 
isoenzymes are located profusely in parietal cells endoplasmic 
reticulum, this enzyme will exert its metabolic biotransformational 
effect over saxagliptin once absorbed, induction effect of sucralose 
over the CYP3A4 metabolic enzyme will also activate the 
metabolism of saxagliptin in liver too, which results in saxagliptin 
plasma/serum levels reduction and over production of saxagliptin 
active and inactive metabolites. 
In rats, CYP3A1, 3A2, 3A9, 3A18, 3A23 and 3A62 have been reported 
as CYP3A forms. CYP3A23 was classified as identical to CYP3A1 by 
the analysis of its gene. 
CYP3A62 form has been identified as a new rat CYP3A isoenzyme 
with expression profile similar to human CYP3A4 and rat CYP3A9. 
CYP3A62 is a predominant form in the intestinal tract, where 
CYP3A1 and-3A2 were found only in liver [17].  
As recent studies illustrated a distinctive binding affinity variance of 
saxagliptin to reactive sites of CYP3A enzymes during metabolic 
reactions which justifies its variable bioavailability between humans 
and rats, this variance impresses a possible perceptible clinical 
differences in saxagliptin human plasma levels when combined with 
sucralose, which strongly recommends further clinical research in 
human. 
CONCLUSION 
A successful HPLC method was validated and developed to quantify 
saxagliptin in rat’s serum, the method was precise and accurate with 
rational linearity performance and reasonable sensitivity and 
selectivity. 
Concerning stability and recovery tests, all obtained results were 
reasonable and accepted according to EMEA guidelines. 
Combination effect of saxagliptin with sucralose over all time 
intervals of saxagliptin serum profile was demonstrated as strong 
statistical effect according to Cohen’s d and significant P values too. 
Cmax showed a significant change between presence and absence of 
sucralose while Tmax didn’t show any change, which suggests the 
possibility of interaction between saxagliptin and sucralose during 
combination. 
Advanced clinical research on human volunteers to make more 
precise results concerning saxagliptin–sucralose combination 
interaction is suggested through the detection and quantification of 
saxagliptin and its active metabolites as these metabolites are also 
pharmacologically active in the human body of the diabetic patient.  
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